MedTrace Logo

Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck

NCT01333696 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-03-05

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and neck.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Ye Guo, MD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-04-30
Completion
2013-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01333696 on ClinicalTrials.gov